[go: up one dir, main page]

PT2678011T - Combinação antitumoral que compreende cabazitaxel e cisplatina - Google Patents

Combinação antitumoral que compreende cabazitaxel e cisplatina

Info

Publication number
PT2678011T
PT2678011T PT12706546T PT12706546T PT2678011T PT 2678011 T PT2678011 T PT 2678011T PT 12706546 T PT12706546 T PT 12706546T PT 12706546 T PT12706546 T PT 12706546T PT 2678011 T PT2678011 T PT 2678011T
Authority
PT
Portugal
Prior art keywords
cabazitaxel
cisplatin
antitumoral combination
antitumoral
combination
Prior art date
Application number
PT12706546T
Other languages
English (en)
Inventor
Bissery Marie-Christine
Dedieu Jean-Francois
Khan Akbar
Vrignaud Patricia
Original Assignee
Sanofi Mature Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45774193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2678011(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP11305204A external-priority patent/EP2491925A1/en
Priority claimed from EP12305109.6A external-priority patent/EP2620148A1/en
Application filed by Sanofi Mature Ip filed Critical Sanofi Mature Ip
Publication of PT2678011T publication Critical patent/PT2678011T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
PT12706546T 2011-02-25 2012-02-24 Combinação antitumoral que compreende cabazitaxel e cisplatina PT2678011T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305204A EP2491925A1 (en) 2011-02-25 2011-02-25 Antitumoral combination comprising cabazitaxel and cisplatin
EP12305109.6A EP2620148A1 (en) 2012-01-27 2012-01-27 Antitumoral combination comprising cabazitaxel and cisplatin

Publications (1)

Publication Number Publication Date
PT2678011T true PT2678011T (pt) 2019-09-26

Family

ID=45774193

Family Applications (1)

Application Number Title Priority Date Filing Date
PT12706546T PT2678011T (pt) 2011-02-25 2012-02-24 Combinação antitumoral que compreende cabazitaxel e cisplatina

Country Status (15)

Country Link
US (2) US20140056996A1 (pt)
EP (1) EP2678011B1 (pt)
AR (1) AR085399A1 (pt)
CY (1) CY1122357T1 (pt)
DK (1) DK2678011T3 (pt)
ES (1) ES2745506T3 (pt)
HR (1) HRP20191322T1 (pt)
HU (1) HUE046232T2 (pt)
LT (1) LT2678011T (pt)
PL (1) PL2678011T3 (pt)
PT (1) PT2678011T (pt)
SI (1) SI2678011T1 (pt)
TW (1) TWI598097B (pt)
UY (1) UY33923A (pt)
WO (1) WO2012113897A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
TW201540296A (zh) * 2014-01-13 2015-11-01 Aventis Pharma Sa 使用卡巴利他賽（ｃａｂａｚｉｔａｘｅl）於患有晚期胃腺癌且於先前化療療程已失敗的病患之用途
CN110384679A (zh) * 2018-04-16 2019-10-29 广州铠宝蕊医药科技有限公司 卡巴他赛白蛋白纳米粒制剂及其制备方法与应用
WO2022056396A1 (en) * 2020-09-14 2022-03-17 Zhuhai Beihai Biotech Co., Ltd. Formulations of cabazitaxel

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
SI1493556T1 (sl) 2003-07-02 2006-02-28 Scheuten Glasgroep Bv Postopek za pripravo protipozarne zasteklitve
FR2945211A1 (fr) * 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine

Also Published As

Publication number Publication date
HRP20191322T1 (hr) 2019-10-18
ES2745506T3 (es) 2020-03-02
CY1122357T1 (el) 2021-01-27
TWI598097B (zh) 2017-09-11
PL2678011T3 (pl) 2019-12-31
WO2012113897A1 (en) 2012-08-30
LT2678011T (lt) 2019-12-10
TW201249435A (en) 2012-12-16
HUE046232T2 (hu) 2020-02-28
EP2678011A1 (en) 2014-01-01
AR085399A1 (es) 2013-09-25
UY33923A (es) 2012-09-28
SI2678011T1 (sl) 2019-09-30
DK2678011T3 (da) 2019-09-23
US20140056996A1 (en) 2014-02-27
US20180153931A1 (en) 2018-06-07
EP2678011B1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
HRP20190135T1 (hr) 4-imidazopiridazin-1-yl-benzamidi i 4-imidazotriazin-1-yl-benzamidi kao inhibitori btk
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
HUE042284T2 (hu) Inhalátor
HK1203424A1 (en) Inhaler
AU345543S (en) Inhaler
IL229844B (en) Anti-psgl-1 antibodies and their use
EP2716359A4 (en) COMPLEX AND USES THEREOF
PT2790739T (pt) Nanopartículas e utilizações das mesmas
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
SG10201602309VA (en) Taxane and abeo-taxane analogs
PL2678011T3 (pl) Kombinacja przeciwnowotworowa zawierająca kabazytaksel i cisplatynę
PT2829180T (pt) Agente para aumento do teor em açúcar de frutos
IL234631A0 (en) Integrated gas processing
PL2934593T3 (pl) Kompozycja kabazytakselu
GB201119171D0 (en) Gas treatment
GB201211135D0 (en) Treatment
GB201208690D0 (en) Treatment
GB201212604D0 (en) New treatment
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder